Retrospective analysis of the clinical efficacy of a dendritic cell-based cancer vaccine in patients with advanced or recurrent breast cancer

DC vaccine-based immunotherapy demonstrates promising OS times and tolerable toxicities in the setting of breast carcinoma. A full risk/benefit analysis of DC-based vaccines in patients with metastatic breast carcinoma will be determined in a future phase II trial.